CJC-1295 NO DAC

CJC-1295 NO DAC is a synthetic compound that acts as an analogue of the growth hormone-releasing hormone (GHRH), or somatoliberin, both after a single and multiple administrations. It also increases the level of insulin-like growth factor 1 (IGF-1) in plasma.

A significant advantage of this compound is that it has been used in comprehensive scientific research on animal models. This enables the estimation of the most effective dosing, potential side effects, and risks associated with its use.

The peptide was first described in 2006, and its creation is attributed to the Canadian company ConjuChem Biotechnologies.